Genomics and proteomics are changing discovery, development and clinical use of dementia drugs

Bibliography

• KEHOE P, WAVRANT-DE VRIEZE F, CROOK R et al.: A full genome scan for late onset Alzheimer’s disease. Hum. Mol Genet. (1999) 8:237-245.
   PubMed Web of Science ®Google Scholar
• CAVALLARO S, CALISSANO P: A genomic approach to investigate neuronal apoptosis. Curr. Alzheimer Res. (2006) 3:285-296.
   Web of Science ®Google Scholar
• PAPASSOTIROPOULOS A, FOUNTOULAKIS M, DUNCKLEY T et al.: Genetics, transcriptomics, and proteomics of Alzheimer’s disease. J. Clin. Psychiatry (2006) 67:652-670.
   Google Scholar
• FARLOW MR, LAHIRI DK, POIRIER J et al.: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology (1998) 50:669-677.
   PubMed Web of Science ®Google Scholar
• POIRIER J, DELISLE MC, QUIRION R et al.: Apolipoprotein E4 allele as predictor of cholinergic deficits and treatment outcome in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA (1995) 92:12260-12264.
   Google Scholar
• BORRONI B, COLCIAGHI F, PASTORINO L et al.: ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer’s disease: evidence from a peripheral model. Eur. Neuropsychopharmacol. (2002) 12:195-200.
   Google Scholar
• BIZZARRO A, MARRA C, ACCIARRI A et al.: Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement. Geriatr Cogn Disord. (2005) 20:254-261.
   PubMed Web of Science ®Google Scholar
• BABIC T, LAKUSIC DM, SERTIC J et al.: ApoE genotyping and response to galanthamine in Alzheimer’s disease – a real life retrospective study. Coll. Antropol. (2004) 28:199-204.
   PubMed Web of Science ®Google Scholar
• FARLOW MR, CYRUS PA, NADEL A et al.: Metrifonate treatment of AD: influence of APOE genotype. Neurology (1999) 53:2010-2016.
   PubMed Web of Science ®Google Scholar
• VISSER PJ, SCHELTENS P, PELGRIM E et al.: Medial temporal lobe atrophy and APoE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer’s disease patients. Dement. Geriatr. Cogn. Disord. (2005) 19:126-133.
   PubMed Web of Science ®Google Scholar
• FARLOW M, LANE R, KUDARAVALLI S et al.: Differential qualitative responses to rivastigmine in APoE epsilon 4 carriers and noncarriers. Pharmacogenomics J. (2004) 4:332-335.
   Web of Science ®Google Scholar
• RIGAUD AS, TRAYKOV L, LATOUR F et al.: Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics (2002) 12:415-420.
   PubMedGoogle Scholar
• SUH GH, JUNG HY, LEE CU et al.: Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer’s disease. Dement. Geriatr Cogn. Disord. (2006) 21:33-39.
   PubMed Web of Science ®Google Scholar
• SAMOCHOCKI M, ZERLIN M, JOSTOCK R et al.: Galantamine is an allosterically potentiating ligand of the human a4/b2 nAChR. Acta Neurol. Scand. Suppl. (2000) 176:68-73.
   Google Scholar
• SANCHEZ L, ALVAREZ V, GONZALEZ P et al.: Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer’s disease. Am. J. Med. Genet. (2001) 105:76-78.
   PubMed Web of Science ®Google Scholar
• SCHUTTE DL, MAAS M, BUCKWALTER KC: A LRPAP1 intronic insertion/deletion polymorphism and phenotypic variability in Alzheimer’s disease. Res. Theory. Nurs. Pract. (2003) 17:301-319.
   PubMedGoogle Scholar
• BEFFERT U, ARGUIN C, POIRIER J: The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer’s disease. Neurosci. Lett (1999) 259:29-32.
   PubMed Web of Science ®Google Scholar
• MONACO EA, III: Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer’s disease. Curr Alzheimer Res. (2004) 1:33-38.
   Web of Science ®Google Scholar
• JACOBS EH, WILLIAMS RJ, FRANCIS PT: Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11 αprotein upregulation in Alzheimer’s disease. Neuroscience (2006) 138:511-522.
   PubMed Web of Science ®Google Scholar
• FARIN FM, JANSSEN P, QUIGLEY S et al.: Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson’s disease. Pharmacogenetics (2001) 11:703-708.
   PubMedGoogle Scholar
• KEHOE PG, RUSS C, MCILORY S et al.: Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer’s disease. Nat.Genet. (1999) 21:71-72.
   PubMed Web of Science ®Google Scholar
• MENG Y, BALDWIN CT, BOWIRRAT A et al.: Association of polymorphisms in the angiotensin-converting enzyme gene with Alzheimer’s disease in an Israeli Arab community. Am. J. Hum. Genet. (2006) 78:871-877.
   PubMed Web of Science ®Google Scholar
• PURANDARE N, OUDE VOSHAAR RC, DAVIDSON Y et al.: Deletion/insertion polymorphism of the angiotensin-converting enzyme gene and white matter hyperintensities in dementia: a pilot study. J. Am. Geriatr. Soc. (2006) 54:1395-1400.
   Web of Science ®Google Scholar
• LEHMANN DJ, CORTINA-BORJA M, WARDEN DR et al.: Large meta-analysis establishes the ACE insertion–deletion polymorphism as a marker of Alzheimer’s disease. Am. J. Epidemiol. (2005) 162:305-317.
   Web of Science ®Google Scholar
• OBA R, IGARASHI A, KAMATA M et al.: The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide. Eur J. Neurosci. (2005) 21:733-740.
   Google Scholar
• LARNER AJ, DORAN M: Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J. Neurol. (2006) 253:139-158.
   Google Scholar
• CHECLER F, VES DA CC, AYRAL E et al.: JLK inhibitors: isocoumarin compounds as putative probes to selectively target the γ-secretase pathway. Curr. Alzheimer Res. (2005) 2:327-334.
   Google Scholar
• SUZUKI H, TAKEDA M, KATO Y et al.: Cathepsin D activities in dementia brains and the degradation of neurofilament proteins with cathepsin D. Neurochem.Res (1988) 13:264.
   Google Scholar
• DAVIDSON Y, GIBBONS L, PRITCHARD A et al.: Genetic associations between cathepsin D exon 2 C- > T polymorphism and Alzheimer’s disease, and pathological correlations with genotype. J. Neurol. Neurosurg. Psychiatr. (2006) 77:515-517.
   Google Scholar
• GAN L, YE S, CHU A et al.: Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J. Biol. Chem. (2004) 279:5565-5572.
   PubMed Web of Science ®Google Scholar
• ANGULO E, NOE V, CASADO V et al.: Upregulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer’s disease. J. Neurochem. (2004) 91:547-557.
   Google Scholar
• PAN Y, XU X, TONG X et al.: Messenger RNA and protein expression analysis of voltage-gated potassium channels in the brain of Aβ(25-35)-treated rats. J. Neurosci. Res. (2004) 77:94-99.
   Google Scholar
• GRUNBLATT E, HOYER S, RIEDERER P: Gene expression profile in streptozotocin rat model for sporadic Alzheimer’s disease. J. Neural Transm. (2004) 111:367-386.
   Google Scholar
• CHIBA T, YAMADA M, HASHIMOTO Y et al.: Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer’s disease-relevant insults in vitro and in vivo. J. Neurosci. (2005) 25:10252-10261.
   Google Scholar
• YING G, IRIBARREN P, ZHOU Y et al.: Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. (2004) 172:7078-7085.
   Google Scholar
• MIGEOTTE I, COMMUNI D, PARMENTIER M: Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. (2006) 17:501-519.
   PubMed Web of Science ®Google Scholar
• IADECOLA C, GOLDMAN SS, HARDER DR et al.: Recommendations of the National Heart, Lung, and Blood Institute working group on cerebrovascular biology and disease. Stroke (2006) 37:1578-1581.
   PubMed Web of Science ®Google Scholar